Abstract 242MO
Background
Loss of skeletal muscle or sarcopenia is commonly seen in various types of malignancy, including ovarian cancer. While some studies suggest sarcopenia as prognostic factor associated with poor survival during chemotherapy, other studies shown no significant association between the two. This meta-analysis aims to investigate whether or not sarcopenia significantly associated with poor survival in ovarian cancer patients undergoing chemotherapy.
Methods
A systematic review was conducted using PRISMA guideline. Online databases (PubMed, PubMed Central and Google Scholar) were searched for relevant terms related to sarcopenia in ovarian cancer patients undergoing chemotherapy with overall survival as our outcome in this study. We used Newcastle Ottawa Scale to assess the quality of our studies. Meta-analysis was later performed using Review Software Manager.
Results
A total of 4 studies are eligible and therefore included in the analysis. All studies were observational studies consisting 653 patients with ovarian cancer. Our included studies each shows “good” quality according to Newcastle Ottawa Scale. Our meta-analysis showed no significant association between sarcopenia and overall survival in ovarian cancer patients receiving chemotherapy (HR 1.54; 95% CI 0.98-2.42; P = 0.06).
Conclusions
Our study result shows that sarcopenia did not influence overall survival of ovarian cancer patients receiving chemotherapy. Future studies should involve more number of patients.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
239MO - NUWA Project: the first national real-world gynecological oncology research and patient management platform in China
Presenter: Qinglei Gao
Session: Mini oral session on Gynaecological tumours
Resources:
Abstract
Webcast
240MO - Disparities in the radiotherapy management of cervical carcinoma across the globe-DOES THE INCIDENCE PATTERN MATCH THE INFRASTRUCTURE AVAILABILITY?
Presenter: Krithikaa Sekar
Session: Mini oral session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
241MO - Survival impact of pretreatment absolute lymphocyte count in cervical cancer patients receiving definitive chemoradiation
Presenter: Elizabeth Yuen Hing Chuk
Session: Mini oral session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 239MO and 240MO
Presenter: Pearly Khaw
Session: Mini oral session on Gynaecological tumours
Resources:
Slides
Webcast
Invited Discussant abstracts 241MO and 242MO
Presenter: David SP Tan
Session: Mini oral session on Gynaecological tumours
Resources:
Slides
Webcast
LIVE Q&A
Presenter: Isabelle Ray-Coquard
Session: Mini oral session on Gynaecological tumours
Resources:
Webcast
LIVE Q&A
Presenter: Isabelle Ray-Coquard
Session: Mini oral session on Gynaecological tumours
Resources:
Webcast